The roles of nuclear miRNAs in cardiovascular disease

Abstract

MicroRNAs (miRNAs) represent a group of endogenous, single-stranded, small non-coding RNAs. Classically, mature miRNAs are in the cytoplasm where they mediate gene silencing by complementary pairing between their seed sequences (nucleotides 2-8 at the 5' end) and target mRNA 3' untranslated regions. However, many subsequent studies have documented the nuclear localization of miRNAs and unraveled their distinct biological roles beyond canonical cytoplasmic functions. In this review, we summarize the non-canonical roles of nuclear miRNAs in key cardiovascular pathologies to deepen our understanding of the miRNA regulatory network in cardiovascular disease and to provide a theoretical rationale for developing next-generation precision miRNA-targeted therapeutics.

Keywords

miRNA / cytoplasm / nuclear / cardiovascular diseases

References

[1] Bartel DP.Metazoan MicroRNAs.Cell2018;173:20-51

[2] Shang R,Senavirathne G.microRNAs in action: biogenesis, function and regulation.Nat Rev Genet2023;24:816-33 PMCID:PMC11087887

[3] Lee RC,Ambros V.The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.Cell1993;75:843-54

[4] Meister G,Patkaniowska A,Teng G.Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.Mol Cell2004;15:185-97

[5] Liao J,Guo Y.Deep sequencing of human nuclear and cytoplasmic small RNAs reveals an unexpectedly complex subcellular distribution of miRNAs and tRNA 3′ trailers.PLoS ONE2010;5:e10563 PMCID:PMC2871053

[6] Billi M,Gentile M,Grignani F.Nuclear miRNAs: gene regulation activities.Int J Mol Sci2024;25:6066 PMCID:PMC11172810

[7] Liu H,He Q,Xiao D.Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer.Mol Cancer2018;17:64 PMCID:PMC5822656

[8] Santovito D.Non-canonical features of microRNAs: paradigms emerging from cardiovascular disease.Nat Rev Cardiol2022;19:620-38

[9] Costa S,Cavalieri V.Epigenetic regulation of chromatin functions by MicroRNAs and long noncoding RNAs and implications in human diseases.Biomedicines2025;13:725 PMCID:PMC11939841

[10] Li H,Chen C.MicroRNAs in cardiovascular diseases.Med Rev2022;2:140-68 PMCID:PMC10471109

[11] Sessa F,Esposito M,Pomara C.miRNA dysregulation in cardiovascular diseases: current opinion and future perspectives.Int J Mol Sci2023;24:5192 PMCID:PMC10048938

[12] Zhou S,Wang J.miRNAS in cardiovascular diseases: potential biomarkers, therapeutic targets and challenges.Acta Pharmacol Sin2018;39:1073-84 PMCID:PMC6289363

[13] Nappi F.Non-coding RNA-targeted therapy: a state-of-the-art review.Int J Mol Sci2024;25:3630 PMCID:PMC11011542

[14] Kim H,Kim VN.The biogenesis and regulation of animal microRNAs.Nat Rev Mol Cell Biol2024;26:276-96

[15] Komatsu S,Suzuki HI.Network regulation of microRNA biogenesis and target interaction.Cells2023;12:306 PMCID:PMC9856966

[16] Zeng Y,Cullen BR.Recognition and cleavage of primary microRNA precursors by the nuclear processing enzyme Drosha.EMBO J2004;24:138-48 PMCID:PMC544904

[17] Lee Y,Han J.The nuclear RNase III Drosha initiates microRNA processing.Nature2003;425:415-9

[18] Lee Y,Lee JT,Kim VN.MicroRNA maturation: stepwise processing and subcellular localization.EMBO J2002;21:4663-70 PMCID:PMC126204

[19] Chendrimada TP,Kumaraswamy E.TRBP recruits the dicer complex to Ago2 for microRNA processing and gene silencing.Nature2005;436:740-4 PMCID:PMC2944926

[20] Suzuki HI,Yasuda T.Small-RNA asymmetry is directly driven by mammalian Argonautes.Nat Struct Mol Biol2015;22:512-21

[21] Iwasaki S,Yoda M.Hsc70/Hsp90 chaperone machinery mediates ATP-dependent RISC loading of small RNA duplexes.Mol Cell2010;39:292-9

[22] Abel Y,Virciglio C.The interaction between RPAP3 and TRBP reveals a possible involvement of the HSP90/R2TP chaperone complex in the regulation of miRNA activity.Nucleic Acids Res2022;50:2172-89 PMCID:PMC8887487

[23] Lund E,Calado A,Kutay U.Nuclear export of MicroRNA precursors.Science2004;303:95-8

[24] Ritland Politz JC,Pederson T.MicroRNA-206 colocalizes with ribosome-rich regions in both the nucleolus and cytoplasm of rat myogenic cells.Proc Natl Acad Sci USA2006;103:18957-62 PMCID:PMC1748159

[25] Ritland Politz JC,Pederson T.MicroRNAs with a nucleolar location.RNA2009;15:1705-15 PMCID:PMC2743059

[26] Robb GB,Khurana J.Specific and potent RNAi in the nucleus of human cells.Nat Struct Mol Biol2005;12:133-7

[27] Hwang H,Mendell JT.A hexanucleotide element directs MicroRNA nuclear import.Science2007;315:97-100

[28] Jeffries CD,Perkins DO.Nuclear and cytoplasmic localization of neural stem cell microRNAs.RNA2011;17:675-86 PMCID:PMC3062178

[29] Guang S,Pavelec DM.An argonaute transports siRNAs from the cytoplasm to the nucleus.Science2008;321:537-41 PMCID:PMC2771369

[30] Wei Y,Wang D,Zen K.Importin 8 regulates the transport of mature MicroRNAs into the cell nucleus.J Biol Chem2014;289:10270-5 PMCID:PMC4036152

[31] Weinmann L,Ivacevic T.Importin 8 is a gene silencing factor that targets argonaute proteins to distinct mRNAs.Cell2009;136:496-507

[32] Schraivogel D,Danner J.Importin-β facilitates nuclear import of human GW proteins and balances cytoplasmic gene silencing protein levels.Nucleic Acids Res2015;43:7447-61 PMCID:PMC4551936

[33] Nishi K,Nagasawa T.Human TNRC6A is an Argonaute-navigator protein for microRNA-mediated gene silencing in the nucleus.RNA2013;19:17-35 PMCID:PMC3527724

[34] Sobti M,Stewart AG,Christie M.Molecular basis for GIGYF-TNRC6 complex assembly.RNA2023;29:724-34 PMCID:PMC10187677

[35] Johnson KC,Hofman C.Nuclear localization of Argonaute 2 is affected by cell density and may relieve repression by microRNAs.Nucleic Acids Res2024;52:1930-52 PMCID:PMC10899759

[36] Pitchiaya S,Park JI,Walter NG.Resolving subcellular miRNA trafficking and turnover at single-molecule resolution.Cell Rep2017;19:630-42 PMCID:PMC5482240

[37] Liu X,Lin X.Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms.Eur Heart J2021;42:4847-61

[38] Xie R,Hu G.Nuclear AGO2 promotes myocardial remodeling by activating ANKRD1 transcription in failing hearts.Mol Ther2024;32:1578-94 PMCID:PMC11081878

[39] Zhang Y,Zhang X.Cellular microRNAs up-regulate transcription via interaction with promoter TATA-box motifs.RNA2014;20:1878-89 PMCID:PMC4238354

[40] Bai Y,Zhan X,Li J.MicroRNA 195-5p targets Foxo3 promoter region to regulate its expression in granulosa cells.Int J Mol Sci2021;22:6721 PMCID:PMC8267755

[41] Wan D,Liang F,Zhang C.The role of miR-3188-mediated transcriptional activation of IL-7Rα in tumor immunotherapy research.Mol Immunol2026;189:142-52

[42] Zisoulis DG,Chang RK.Autoregulation of microRNA biogenesis by let-7 and Argonaute.Nature2012;486:541-4 PMCID:PMC3387326

[43] Tang R,Zhu D.Mouse miRNA-709 directly regulates miRNA-15a/16-1 biogenesis at the posttranscriptional level in the nucleus: evidence for a microRNA hierarchy system.Cell Res2011;22:504-15 PMCID:PMC3292299

[44] Wang D,Wei Y.Nuclear miR-122 directly regulates the biogenesis of cell survival oncomiR miR-21 at the posttranscriptional level.Nucleic Acids Res2018;46:2012-29 PMCID:PMC5829740

[45] La Rocca G.Roles of the core components of the mammalian miRISC in chromatin biology.Genes2022;13:414 PMCID:PMC8954937

[46] El Fatimy R,Deforzh E.A nuclear function for an oncogenic microRNA as a modulator of snRNA and splicing.Mol Cancer2022;21:17 PMCID:PMC8760648

[47] Santovito D,Bidzhekov K.Noncanonical inhibition of caspase-3 by a nuclear microRNA confers endothelial protection by autophagy in atherosclerosis.Sci Transl Med2020;12:eaaz2294

[48] Xie H,Ling Z.Oral pathogen aggravates atherosclerosis by inducing smooth muscle cell apoptosis and repressing macrophage efferocytosis.Int J Oral Sci2023;15:26 PMCID:PMC10307898

[49] Meng F,Liang Q,Huang Y.The Lnc-RNA APPAT suppresses human aortic smooth muscle cell proliferation and migration by interacting with MiR-647 and FGF5 in Atherosclerosis.J Endovasc Ther2022;30:937-50

[50] Mathiyalagan P,Chang L,Du X.The primary microRNA-208b interacts with polycomb-group protein, Ezh2, to regulate gene expression in the heart.Nucleic Acids Res2013;42:790-803 PMCID:PMC3902903

[51] Fan J,Nie X.Nuclear miR-665 aggravates heart failure via suppressing phosphatase and tensin homolog transcription.Sci China Life Sci2019;63:724-36

[52] Li H,Zhao Y.Nuclear miR-320 mediates diabetes-induced cardiac dysfunction by activating transcription of fatty acid metabolic genes to cause lipotoxicity in the heart.Circ Res2019;125:1106-20 PMCID:PMC6903355

[53] Zhan J,Ding N.Positive feedback loop of miR-320 and CD36 regulates the hyperglycemic memory-induced diabetic diastolic cardiac dysfunction.Mol Ther Nucleic Acids2023;31:122-38 PMCID:PMC9813582

[54] Khan AW,Corcoran SJ.NET silencing by let-7i in postural tachycardia syndrome.JCI Insight2017;2:e90183 PMCID:PMC5358482

[55] Di Mauro V,Colombo FS,Catalucci D.Wnt signalling mediates miR-133a nuclear re-localization for the transcriptional control of Dnmt3b in cardiac cells.Sci Rep2019;9:9320 PMCID:PMC6597717

[56] Björkegren JL.Atherosclerosis: recent developments.Cell2022;185:1630-45 PMCID:PMC9119695

[57] Libby P.The changing landscape of atherosclerosis.Nature2021;592:524-33

[58] Souilhol C,Fragiadaki M.Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes.Nat Rev Cardiol2019;17:52-63

[59] Wei Y,Neth P,Schober A.MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?.Arterioscler Thromb Vasc Biol2013;33:449-54

[60] Fish JE,Morton SU.miR-126 regulates angiogenic signaling and vascular integrity.Dev Cell2008;15:272-84 PMCID:PMC2604134

[61] Theofilis P,Vogiatzi G.The role of MicroRNA-126 in atherosclerotic cardiovasculardiseases.Curr Med Chem2023;30:1902-21

[62] Schober A,Wei Y.MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1.Nat Med2014;20:368-76 PMCID:PMC4398028

[63] Liu X,Tian R,Deng S.Targeting foam cell formation and macrophage polarization in atherosclerosis: the therapeutic potential of rhubarb.Biomed Pharmacother2020;129:110433

[64] Ma C,Tian M.Gsα regulates macrophage foam cell formation during atherosclerosis.Circ Res2024;134:e34-e51 PMCID:PMC10978275

[65] Tian K,Sahebkar A.CD36 in Atherosclerosis: pathophysiological mechanisms and therapeutic implications.Curr Atheroscler Rep2020;22:59

[66] Crabtree GR.NFAT signaling: choreographing the social lives of cells.Cell2002;109:S67-79

[67] Mozafari M,Ahmad Amin Noordin KB,Azlina A.Nuclear factor of activated T cells (NFAT) proteins as targeted molecules in diseases: a narrative review.Cureus2024;16:e75844 PMCID:PMC11736229

[68] Park Y,Kim M.The role of calcium-calcineurin-NFAT signaling pathway in health and Autoimmune diseases.Front Immunol2020;11:195 PMCID:PMC7075805

[69] Haraszthy V,Trevisan M,Genco R.Identification of periodontal pathogens in Atheromatous plaques.J Periodontol2000;71:1554-60

[70] Xie M,Nie J.BMAL1-downregulation aggravates Porphyromonas gingivalis-induced atherosclerosis by encouraging oxidative stress.Circ Res2020;126

[71] Park S,Han SJ.Oral Porphyromonas gingivalis infection affects intestinal microbiota and promotes atherosclerosis.J Clin Periodontol2023;50:1553-67

[72] Rao A,Subramanyam K.Molecular analysis shows the presence of periodontal bacterial DNA in atherosclerotic plaques from patients with coronary artery disease.Indian Heart J2021;73:218-20 PMCID:PMC8065351

[73] Šubarić A,Mihailović Đ.Detecting oral bacteria in abdominal aorta atherosclerotic plaques—how far can they go?.Medicina2025;61:1976 PMCID:PMC12654703

[74] Meng F,Ma Q.Expression status and clinical significance of lncRNA APPAT in the progression of atherosclerosis.PeerJ2018;6:e4246 PMCID:PMC5775756

[75] Lu S,Huang Y,Liu J.Definition and review on a category of long non-coding RNA: atherosclerosis-associated circulating lncRNA (ASCLncRNA).PeerJ2020;8:e10001 PMCID:PMC7666546

[76] Hang CT,Han P.Chromatin regulation by Brg1 underlies heart muscle development and disease.Nature2010;466:62-7 PMCID:PMC2898892

[77] Guo S,Ling L.Molecular mechanisms and intervention approaches of heart failure (Review).Int J Mol Med2025;56:1-15 PMCID:PMC12180911

[78] Yue P,Wu G.Attenuation of cardiomyocyte hypertrophy via depletion Myh7 using CASAAV.Cardiovasc Toxicol2020;21:255-64

[79] K N H,Mathiyalagan P.Sex-based Mhrt methylation chromatinizes MeCP2 in the heart.iScience2019;17:288-301 PMCID:PMC6639684

[80] Yim E,Dai H.Rak functions as a tumor suppressor by regulating PTEN protein stability and function.Cancer Cell2009;15:304-14 PMCID:PMC2673492

[81] Jha M.Exploring phosphatase and tensin homologue deleted on chromosome ten (PTEN) as a potential therapeutic target for cardiac hypertrophy.ACS Pharmacol Transl Sci2025;8:2312-36 PMCID:PMC12340630

[82] Oudit G,Kerfant BG,Penninger JM.The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease.J Mol Cell Cardiol2004;37:449-71

[83] Oudit GY.Cardiac regulation by phosphoinositide 3-kinases and PTEN.Cardiovasc Res2008;82:250-60

[84] Nie X,Li H.miR-217 promotes cardiac hypertrophy and dysfunction by targeting PTEN.Mol Ther Nucl Acids2018;12:254-66 PMCID:PMC6005806

[85] Huo J,Pan S,Liu Z.Diabetic cardiomyopathy: early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions.Cell Death Discov2023;9:256 PMCID:PMC10362058

[86] Yang J,Han X.CD36 deficiency rescues lipotoxic cardiomyopathy.Circ Res2007;100:1208-17

[87] Rada P,García-Monzón C.Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?.Cell Death Dis2020;11:802 PMCID:PMC7519685

[88] Goldstein DS,Frank SM.Cardiac sympathetic dysautonomia in chronic orthostatic intolerance syndromes.Circulation2002;106:2358-65

[89] Mar PL.Postural orthostatic tachycardia syndrome: mechanisms and new therapies.Annu Rev Med2020;71:235-48

[90] Shannon JR,Jordan J.Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency.N Engl J Med2000;342:541-9

[91] Lambert E,Esler M.Altered sympathetic nervous reactivity and norepinephrine transporter expression in patients with postural tachycardia syndrome.Circ Arrhythm Electrophysiol2008;1:103-9

[92] Okano M,Haber DA.DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development.Cell1999;99:247-57

[93] Ueda Y,Williams C,Georgopoulos K.Roles for Dnmt3b in mammalian development: a mouse model for the ICF syndrome.Development2006;133:1183-92

[94] Khvorova A.The chemical evolution of oligonucleotide therapies of clinical utility.Nat Biotechnol2017;35:238-48 PMCID:PMC5517098

[95] Brillante S,Indrieri A.Advances in MicroRNA therapeutics: from preclinical to clinical studies.Hum Gene Ther2024;35:628-48

[96] Kara G,Ozpolat B.RNAi-based therapeutics and tumor targeted delivery in cancer.Adv Drug Delivery Rev2022;182:114113

[97] Nappi F,Jitendra V,Schoell T.The roles of microRNAs in the cardiovascular system.Int J Mol Sci2023;24:14277 PMCID:PMC10531750

[98] Chakraborty C,Sharma G.Therapeutic advances of miRNAs: a preclinical and clinical update.J Adv Res2021;28:127-38 PMCID:PMC7753224

[99] Bauersachs J,Anker SD.Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: rationale and design of the HF-REVERT trial.Eur J Heart Fail2024;26:674-82

[100] Chioccioli M,Newell R.A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis.eBioMedicine2022;85:104304 PMCID:PMC9587275

[101] Hinkel R,Zühlke S.Inhibition of MicroRNA-92a protects against ischemia/reperfusion injury in a large-animal model.Circulation2013;128:1066-75

[102] Bonauer A,Iwasaki M.MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice.Science2009;324:1710-3

[103] Abplanalp WT,John D.Efficiency and target derepression of anti-miR-92a: results of a first in human study.Nucleic Acid Ther2020;30:335-45

[104] Gallo A,Sciacca S.MicroRNA-30d and -483-3p for Bi-ventricular remodelling and miR-126-3p for pulmonary hypertension in advanced heart failure.ESC Heart Fail2024;11:155-66 PMCID:PMC10804158

[105] Zernecke A,Noels H.Delivery of MicroRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection.Sci Signal2009;2:ra81

[106] Gabisonia K,Aquaro GD.MicroRNA therapy stimulates uncontrolled cardiac repair after myocardial infarction in pigs.Nature2019;569:418-22 PMCID:PMC6768803

[107] Locher MR,Stelzer JE,Patel JR.Determination of rate constants for turnover of myosin isoforms in rat myocardium: implications for in vivo contractile kinetics.Am J Physiol Heart Circ Physiol2009;297:H247-56 PMCID:PMC2711735

[108] Hsieh J,Givens S.Myosin heavy chain converter domain mutations drive early-stage changes in extracellular matrix dynamics in hypertrophic cardiomyopathy.Front Cell Dev Biol2022;10:894635 PMCID:PMC9245526

[109] Mosqueira D,Bhagwan JR.CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depletion as potential therapeutic targets for hypertrophic cardiomyopathy.Eur Heart J2018;39:3879-92 PMCID:PMC6234851

[110] Mitchell PS,Kroh EM.Circulating microRNAs as stable blood-based markers for cancer detection.Proc Natl Acad Sci USA2008;105:10513-8 PMCID:PMC2492472

[111] Weber JA,Zhang S.The MicroRNA spectrum in 12 body fluids.Clin Chem2010;56:1733-41 PMCID:PMC4846276

[112] Arroyo JD,Kroh EM.Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma.Proc Natl Acad Sci USA2011;108:5003-8 PMCID:PMC3064324

[113] Mayr M,Willeit P,Kiechl S.MicroRNAs within the continuum of postgenomics biomarker discovery.Arterioscler Thromb Vasc Biol2013;33:206-14

[114] Vanhaverbeke M,Bartekova M.Peripheral blood RNA biomarkers for cardiovascular disease from bench to bedside: a position paper from the EU-CardioRNA COST action CA17129.Cardiovasc Res2022;118:3183-97 PMCID:PMC9799060

[115] De Gonzalo-Calvo D,Bär C.Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?.Eur Heart J2019;40:1643-50 PMCID:PMC6528150

[116] Viereck J.Circulating noncoding RNAs as biomarkers of cardiovascular disease and injury.Circ Res2017;120:381-99

[117] De Boer HC,Prins J.Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease.Eur Heart J2013;34:3451-7

[118] Willeit P,Dudek K.Circulating MicroRNAs as novel biomarkers for platelet activation.Circ Res2013;112:595-600

[119] Marfella R,Potenza N.Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders.Eur J Heart Fail2013;15:1277-88

[120] De Gonzalo-Calvo D,Rijzewijk LJ.Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes.Sci Rep2017;7:47 PMCID:PMC5428350

[121] Cheng M,Zhao X.Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells.Nat Commun2019;10:959 PMCID:PMC6393447

[122] Morley-Smith AC,Jacobs S.Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device.Eur J Heart Fail2014;16:871-9 PMCID:PMC4145708